Introduction: The aim of the study was to evaluate the contribution of genetic variants determining inherited thrombophilia to recurrent miscarriage (RM) in the Polish population. The following polymorphisms were analyzed: 1691G>A, 1328T>C of coagulation factor V, 20210G>A of coagulation factor II, R353Q (11496G>A) of coagulation factor VII, 667C>T, 1298A>C, 1793G>A of MTHFR.
INTRODUCTION
Polymorphic variants of genes involved in the coagulation cascade and fibrinolysis are believed to play a key role in the etiology of recurrent miscarriage (RM). Inherited thrombophilia may result in significant changes in the utero-placental circulation, including placental infarction, atherosclerotic changes in vessels, and placental insufficiency [1] [2] [3] [4] .
The most common causes of inherited thrombophilia are polymorphisms in genes encoding factor V, prothrombin (factor II), factor VII, methylenetetrahydrofolate reductase (MTHFR), and plasminogen activator inhibitor, while protein C, protein S and antithrombin deficiency is less common. Studies confirming a correlation between inherited thrombophilia and recurrent pregnancy loss have been performed all over the world and concerned diverse ethnic populations [5] [6] [7] .
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One of a number of hypotheses concerning a correlation between inherited thrombophilia and RM is based on the fact that coagulation cascade stimulation caused by endothelial dysfunction is more likely to occur in women with genetic defects of hemostatic factors predisposing to thrombotic changes in the placental circulation [8, 9] . The subsequent complications, especially miscarriage, are probably conditioned by impaired placental development and improper placental perfusion. Thrombotic tendency may be manifested by the so-called 'thrombotic damage of placental circulation' . Those changes are known as the 'pregnancy vascular complications' [10, 11] .
Pregnancy itself is a condition which favors the appearance of physiological hypercoagulability and, with the additional presence of genetic defects of coagulation cascade and fibrinolysis, which may result in serious obstetrical complications, including RM [12, 13] .
The fact that pregnancy-related complications develop only in some carriers of thrombotic mutations remains a source of much controversy, although environmental factors have been mentioned as the possible cause. Numerous maternal hemostatic proteins cooperate with trophoblastic coagulation cascade components. That process is essential for proper embryogenesis. Coagulation proteins are believed to act also as regulatory and signal factors in immunological reactions and cellular proliferation, although further studies are necessary to fully elucidate the matter [14, 15] .
OBJECTIVES
The goal of the research was to evaluate the contribution of genetic variants determining inherited thrombophilia to recurrent miscarriage (RM) in the Polish population. The following polymorphisms were analyzed: 1691G>A, 1328T>C of coagulation factor V, 20210G>A of coagulation factor II, R353Q (11496G>A) of coagulation factor VII, 667C>T, 1793G>A and 1298A>C of MTHFR.
MATERIAL AND METHODS
A total of 359 women with ≥ 2 RM and 400 healthy controls were included in the study. Miscarriage was defined as the 'loss of pregnancy before 22 completed weeks of gestation (w.g.) ' . Gestational age at the time of miscarriage was calculated according to the date of the last menstruation and ultrasound evaluation. All subjects were Caucasian and of Polish origin nationality. The patients were enrolled at the Division of Perinatology and Women's Diseases, Poznan University of Medical Sciences. The study was performed between 2009 and 2015. Local Ethics Committee approved of the study (1082/07, 867/15, 210/16). All patients gave their written informed consent. All participants were taking 400 mg folic acid per day at the time of the study.
Study group
The study group was divided into two subgroups: 303 women with ≥ 2 subsequent RM < 13 w.g. during one relationship and 56 women with ≥ 2 subsequent RM between 13-22 w.g. during one relationship. The presence of protein C, protein S, antithrombin deficiency as well as antiphospholipid syndrome were excluded in all subjects. Each patient had a negative history of thrombotic events. Patients with known reasons for RM (e.g. anatomical anomalies of the genitourinary tract, chromosomal aberrations, acquired thrombophilia, chronic diseases, infections, hormonal disturbances), cervical insufficiency, or other obstetric complications which could be a cause of RM (e.g. hypertension diagnosed in the course of pregnancy, gestational diabetes mellitus, anatomical and genetic fetal defects, serological conflict) were excluded. Only patients with RM of an unknown origin were included into the analysis.
Control group
The control group included 400 healthy women with a medical history of at least two uncomplicated pregnancies ended at term with a delivery of a healthy infant. No miscarriages were recorded in this group. All women positive for miscarriage, other obstetric complications caused by thrombotic changes chronic diseases, acquired thrombophilia (antiphospholipid syndrome), and positive history of thrombotic events were excluded from the analysis. Gestational age at the time of delivery was calculated according to the date of the last menstruation and ultrasound evaluation.
Clinical characteristics of the study population are presented in Table 1 .
Genetic analysis
DNA was isolated from blood leucocytes using QIAamp DNA Blood Mini Kit (QIAGEN Inc., Germany). The frequency of the investigated genetic polymorphisms was assessed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Genetic analysis was performed at the Laboratory of Molecular Biology, Division of Perinatology and Women's Diseases, PUMS. Table 2 presents used primers. Investigated polymorphisms were recognized by adequate restriction enzyme hydrolysis. Hydrolyzed PCR products were analyzed on a 2% agarose gel. Visualization was performed under UV light.
Statistical methods
Statistical analyses were performed using SPSS22.0 PL for Windows. The p-value of < 0.05 was considered as statistically significant. Genotype frequencies were compared by chi-square test (one-sided Fisher test). The expected genotype frequencies were calculated from allele frequencies with the use of the Hardy-Weinberg equation.
RESULTS
There were no statistically significant correlations for the 1691G>A factor V gene polymorphism in both study subgroups and controls. The frequency of the heterozygous 1691GA genotype was comparable in all analyzed groups (7.59% in the RM < 13 w.g. subgroup, 5.36% in the RM 13--22 w.g. subgroup and 5.25% in controls, ns). Also, the occurrence of the mutated 1691A allele was similar in all investigated groups (3.80% in the RM < 13 w.g. subgroup, 2.68% in the RM 13-22 w.g. subgroup, 2.88% in controls, ns) ( Table 3) .
The analysis of the 1328T>C factor V gene polymorphism revealed comparable frequency of its variants. Congenial occurrence of heterozygous 1328TC and homozygous 1328CC genotypes was observed in the RM < 13 w.g. subgroup (23.76% and 1.65%), in the RM 13-22 w.g. subgroup (16.07% and 1.79%) and in controls (22.25% and 1.25%). As for the mutated 1328C allele, a similar frequency was also noted: 13.53% in the RM < 13 w.g. subgroup, 9.82% in the RM 13-22 w.g. subgroup, and 12.38% in controls (Table 4) .
While analyzing the 20210G>A factor II gene polymorphism, higher frequency of the heterozygous 20210GA genotype was observed in the RM < 13 w.g. subgroup (2.97 vs. 1.50% in controls, OR = 2.01, ns) and in the RM 13-22 w.g. subgroup (5.36 vs. 1.50% in controls, OR = 3.72, p = 0.09). The same correlation was found in the mutated 20210A allele -its frequency was higher in the RM < 13 RM subgroup (1.49 vs. 0.75% in controls, OR = 1.99, ns) and in the RM 13-22 w.g. subgroup (2.68 vs. 0.75% in controls, WR = 3.72, p = 0.09) ( Table 5) .
Similar observations were made for the R353Q (11496G>A) factor VII gene polymorphism. Statistically significantly higher frequency of the heterozygous 11496GA genotype was noted in controls as compared to the RM 13-22 w.g. subgroup (10.71 vs. 23.00% in controls, OR = 0.40, p = 0.02). Comparable statistical differences concerned genotypes containing the mutated 11496A allele (GA + AA) in the RM < 13 w.g. subgroup and in controls (12.50 vs. 24.50%, OR = 0.44, p = 0.029). The frequency of the mutated 11496A allele was also higher in controls as compared to the RM 13-22 w.g. subgroup (7.14 vs. 13.00% in controls, OR = 0.51, p = 0.05) ( Table 6 ). As for the 677C>T MTHFR gene polymorphism, the occurrence of genotypes and alleles was similar in all analyzed groups. The frequency of the heterozygous 677CT genotype was comparable in both study subgroups and in controls (42.24% in the RM < 13 w.g. subgroup, 44.64% in the RM 13-22 w.g. subgroup, 41.00% in controls, ns). In case of the mutated 677TT genotype, its frequency was 11.88% in the RM < 13 w.g. subgroup, 8.93% in the RM 13-22 w.g. subgroup, and 8.75% in controls, ns. A similar correlation was found for allele frequency (Table 7) .
For the 1298A>C MTHFR gene polymorphism, the following genotype distribution was observed: in the RM < 13 w.g. (Table 8) .
A similar finding was made about the 1793G>A MTH-FR gene polymorphism. Statistically significantly higher frequency of the heterozygous 1793GA genotype in the RM < 13 w.g. subgroup was noted (12.21 vs. 7.75% in controls, OR = 1.66, p = 0.03). Also, the occurrence of genotypes containing the mutated 1793A allele (1793GA + 1793AA) was significantly higher in the RM < 13 w.g. subgroup (12.54 vs. 8.00% in controls, OR = 1.65, p = 0.03). A statistically significant correlation was found also for the frequency of the mutated 1793A allele, which was higher in the RM < 13 w.g. subgroup (6.44 vs. 4.13% in controls, OR = 1.60, (Table 9) .
DISCUSSION
The present study involved patients with RM as well as healthy controls. It is one of the biggest analyses concerning inherited thrombophilia and RM in the Polish population. The study group is fully representative for that kind of research. Owing to the sample size, the statistical tests are reliable. Significant differences of frequencies of genetic variants between diverse ethnic and regional groups have been reported and that is why eligibility criteria should also include ethnic homogeneity. In our study, all women were Caucasian and of Polish origin. In similar studies, comparing healthy and unhealthy unrelated groups of patients, adequate exclusion and inclusion criteria are of vital importance. Inadequate eligibility criteria and insufficient sample size are the most common reasons of obtaining conflicting results concerning the frequency of genetic polymorphisms [16] . Noteworthy, the abovementioned study considered 7 genetic polymorphisms in 4 genes of coagulation cascade, folate and homocysteine metabolism.
Factor V Leiden (1691G>A) is one of the most commonly analyzed factors involved in the etiology of RM and has been suggested to be the dominant cause of miscarriage in the first and second trimesters of pregnancy. A multi-center study by Skrzypczak et al., performed in 2012, investigated 396 patients with at least one pregnancy loss (122 women with 3 or more early RM, 87 with late RM and 46 with IUFD) and 50 women with a negative history of pregnancy loss. Their results revealed a possible role of the factor V Leiden in the etiology of RM. Additionally, those authors emphasized the need to perform factor V Leiden screening tests among patients with the diagnosis of RM [17] . A study 
